Advertisement

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

2014 ASH Annual Meeting

Advertisement

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Related Videos

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.

Laurie Sehn, MD

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Julie M. Vose, MD, MBA, FASCO

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Myelodysplastic Syndromes

Alan F. List, MD

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients With Higher-Risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents,” presented by Guillermo Garcia-Manero, MD.

Time: 1:54

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Splenectomy in Immune Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Complications After Splenectomy in Adult Chronic Immune Thrombocytopenia With a Minimum Follow-up of 10 Years: First Results From a Single-Center Case-Control Study in 140 Patients With Primary ITP,” presented by Lan-huong Thai.

Advertisement

Advertisement

May

03

Today In Oncology

FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer

Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy

Association of Body Size and Bladder Cancer Risk

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Can PFAS Exposure Raise ALL Risk?

Advertisement

© 2026 HSP News Service, L.L.C.